| Title |
Clinical efficacy and safety of statins in managing cardiovascular risk
|
|---|---|
| Published in |
Vascular Health and Risk Management, April 2008
|
| DOI | 10.2147/vhrm.s1653 |
| Pubmed ID | |
| Authors |
Navin K Kapur, Kiran Musunuru |
| Abstract |
Since their introduction in the 1980s, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have emerged as the one of the best-selling medication classes to date, with numerous trials demonstrating powerful efficacy in preventing cardiovascular outcomes. As our understanding of low-density lipoprotein cholesterol (LDL-C) and atherosclerosis continues to grow, the concept of 'lower is better' has corresponded with a more is better' approach to statin-based therapy. This review provides a detailed understanding of the clinical efficacy and safety of statins with a particular emphasis on the third generation drug, rosuvastatin. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Namibia | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 175 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | <1% |
| Poland | 1 | <1% |
| Unknown | 173 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 37 | 21% |
| Student > Master | 36 | 21% |
| Student > Ph. D. Student | 23 | 13% |
| Researcher | 18 | 10% |
| Student > Postgraduate | 10 | 6% |
| Other | 23 | 13% |
| Unknown | 28 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 28 | 16% |
| Agricultural and Biological Sciences | 24 | 14% |
| Biochemistry, Genetics and Molecular Biology | 17 | 10% |
| Nursing and Health Professions | 4 | 2% |
| Other | 23 | 13% |
| Unknown | 30 | 17% |
Attention Score in Context
This research output has an Altmetric Attention Score of 77. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2022.
All research outputs
#556,841
of 25,374,647 outputs
Outputs from Vascular Health and Risk Management
#17
of 804 outputs
Outputs of similar age
#996
of 95,975 outputs
Outputs of similar age from Vascular Health and Risk Management
#1
of 13 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,975 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.